MEDIPOST Files IND Amendment for Phase III Knee Osteoarthritis Stem Cell Trial
MEDIPOST has submitted an investigational new drug amendment to the FDA to initiate a Phase III trial of its umbilical cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis, with patient enrollment expected in the first half of 2026.
MEDIPOST Inc. has submitted an investigational new drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis. The IND amendment was filed on February 13, 2026, and patient enrollment is expected to begin in the first half of 2026.
The investigational therapy is an umbilical cord blood-derived allogeneic mesenchymal stem cell therapy designed to treat symptomatic cartilage defects in patients with knee osteoarthritis. This amendment aims to advance MEDIPOST's clinical programme for the stem cell therapy targeting this degenerative joint condition.
Knee osteoarthritis is a leading cause of pain and loss of mobility, highlighting the need for therapies that go beyond symptom management. The upcoming Phase III research will determine the role of regenerative cell therapy in addressing this unmet medical need.
The CEO stated that submitting this IND amendment marks an important step toward advancing the U.S. clinical program. The focus is on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition. Filing an IND amendment reflects the company's long-term commitment to advancing science that has the potential to make a meaningful difference for patients.
In January 2026, MEDIPOST announced that its parent company had closed a $140 million funding round led by Skylake Equity Partners and Crescendo Equity Partners, with participation from Korea's growth equity fund. The investment will support the expansion of scientific and operational capacities, infrastructure development, and scaling of manufacturing processes for the Phase III trial for knee osteoarthritis.
MEDIPOST continues to build a portfolio of regenerative medicine products using its stem cell technology platform, focusing on scalable and off-the-shelf therapeutic methods.